Psilocybin – a promising therapy for treatment-resistant depression?

Journal of Psychiatric Practice presents review and update on psychedelics for mental disorders

2023-09-07

(Press-News.org) September 7, 2023 – A growing body of evidence suggests that psychedelic drugs may be useful in treating various mental health conditions. However, many challenges remain in defining their clinical benefits and overcoming the complex regulatory obstacles to their use. The September issue of Journal of Psychiatric Practice presents a research review and update on therapeutic use of psychedelics – focusing on the use of psilocybin for treatment of depression. The journal is published in the Lippincott portfolio in partnership with Wolters Kluwer.

“At a time of growing excitement regarding the potential use of psychedelic agents to improve outcomes of otherwise intractable disorders, psychiatrists and patients alike need perspective on the current state of the evidence and the prospects moving forward,” comments lead author Amir Garakani, MD, of Greenwich Hospital, Greenwich, Conn., and the Department of Psychiatry at the Yale School of Medicine, New Haven, Conn.

"In this article, members of the Psychopharmacology Committee of the Group for the Advancement of Psychiatry and consultants discuss current research findings to provide guidance to clinicians concerning the prospects for psilocybin treatment for their patients struggling with debilitating depression."

The psychedelic experience – how does psilocybin affect the brain?

Psilocybin is a naturally occurring psychedelic substance found in so-called "magic mushrooms." Many recent clinical trials have reported positive effects of psilocybin in treating psychiatric disorders, including major depressive disorder (MDD) and treatment-resistant depression (TRD).

Evidence suggests that therapeutic responses to psilocybin "stem from, or at least go hand-in-hand with, an intense emotional or mystical experience," Dr. Garakani and colleagues write. Studies suggest that psilocybin leads to increased "openness to experience" and psychological flexibility – enabling patients to "reconsider stereotyped perspectives and move beyond accustomed patterns of thinking."

Research into psilocybin's biological effects suggest increased activity between brain networks, without corresponding increases within single networks. Greater changes in brain network flexibility have been linked to lasting reductions in depression symptoms six months later.

Clinical trials show progress – but research questions and regulatory issues remain

To date, all psilocybin treatment studies have included a psychotherapy component, including preparation, dosing, and integration phases. In integration sessions, "Participants are encouraged to share their experiences, with the goal of helping them generate insights, and facilitating behavioral change," according to the authors.

Various dosing strategies are being evaluated in academic and commercial settings. These studies follow highly controlled protocols in carefully selected populations, with special attention to maximizing patient safety during the psychedelic experience.

Clinical trial registries show a "multitude" of studies planned or in progress, targeting MDD, TRD, and other conditions such as cancer-related anxiety and post-traumatic stress disorder. "The large number and wide-ranging scope of ongoing and future psilocybin trials not only show the interest in this drug in the scientific community but also the potential therapeutic role of psychedelics across diagnoses and clinical domains," the researchers write.

Earlier this year, the Australian regulatory agency announced approval for psychiatrists to prescribe psilocybin treatment for TRD. In the United States, psilocybin has been designated as a "breakthrough therapy" for TRD and MDD. While two states have legalized or decriminalized psilocybin (Oregon and Colorado, respectively), it remains a Schedule 1 controlled substance under federal law.

An official American Psychiatric Association position states that there is "currently inadequate scientific evidence" to endorse the use of psychedelics for treatment of any psychiatric disorder, outside of approved research studies. Nevertheless, "The research evidence presented here offers further support for the potential of psychedelics in mental health care," Dr. Garakani and colleagues conclude.

"Psilocybin has demonstrated promise as a novel therapeutic and offers new perspectives on the function and dysfunction of the brain," according to the authors. However, they add: "[I]t remains to be seen if the current clinical, legal, and research landscapes will allow delivery on that promise."

Read Paper [Psychedelics, With a Focus on Psilocybin: Issues for the Clinician]

Wolters Kluwer provides trusted clinical technology and evidence-based solutions that engage clinicians, patients, researchers and students in effective decision-making and outcomes across healthcare. We support clinical effectiveness, learning and research, clinical surveillance and compliance, as well as data solutions. For more information about our solutions, visit https://www.wolterskluwer.com/en/health and follow us on LinkedIn and Twitter @WKHealth.

###

About Journal of Psychiatric Practice

Journal of Psychiatric Practice®, a peer reviewed journal, publishes reports on new research, clinically applicable reviews, articles on treatment advances, and case studies, with the goal of providing practical and informative guidance for clinicians. Mental health professionals will want access to this journal—for sharpening their clinical skills, discovering the best in treatment, and navigating this rapidly changing field. John M. Oldham, MD, is the editor in chief and past president of the American Psychiatric Association.

About Wolters Kluwer

Wolters Kluwer (EURONEXT: WKL) is a global leader in professional information, software solutions, and services for the healthcare, tax and accounting, financial and corporate compliance, legal and regulatory, and corporate performance and ESG sectors. We help our customers make critical decisions every day by providing expert solutions that combine deep domain knowledge with specialized technology and services.

Wolters Kluwer reported 2022 annual revenues of €5.5 billion. The group serves customers in over 180 countries, maintains operations in over 40 countries, and employs approximately 20,900 people worldwide. The company is headquartered in Alphen aan den Rijn, the Netherlands.

For more information, visit www.wolterskluwer.com, follow us on LinkedIn, Twitter, Facebook, and YouTube.

END

ELSE PRESS RELEASES FROM THIS DATE:

NASA’s Swift learns a new trick, spots a snacking black hole

2023-09-07

Using NASA’s Neil Gehrels Swift Observatory, which launched in 2004, scientists have discovered a black hole in a distant galaxy repeatedly nibbling on a Sun-like star. The object heralds a new era of Swift science made possible by a novel method for analyzing data from the satellite’s X-ray Telescope (XRT). “Swift’s hardware, software, and the skills of its international team have enabled it to adapt to new areas of astrophysics over its lifetime,” said Phil Evans, an astrophysicist at the University of Leicester in the United Kingdom and longtime Swift team member. “Neil Gehrels, the ...

U of M study suggests hepatitis C patients should consider revaccination for hepatitis B

2023-09-07

MINNEAPOLIS/ST. PAUL (09/07/2023) — Recently published research from the University of Minnesota Medical School suggests individuals with hepatitis C should consider revaccination for hepatitis B. The study was published in the Journal of Infectious Diseases. Previous research has shown individuals with hepatitis C infection have a lower response to the hepatitis B virus (HBV) vaccine. “This study has broad implications for public health in hepatitis-infected individuals,” said Jose Debes, MD, PhD, an ...

NYU Tandon School of Engineering researchers develop hurricane power outage prediction model that outperforms traditional methods

2023-09-07

Utility companies are generally well-equipped to handle routine blackouts, but often struggle with extreme weather events like hurricanes. Conventional hurricane power-outage prediction models often produce incomplete or incorrect results, hampering companies’ abilities to prepare to restore power as quickly as possible, especially in cities that are susceptible to prolonged hurricane-induced power outages. New research from NYU Tandon School of Engineering may help solve that problem. By combining wind speed and precipitation ...

Cattle on low-protein rations may need amino acid supplement to boost milk yield

2023-09-07

UNIVERSITY PARK, Pa. — When dairy cows are fed diets with reduced protein concentrations — aimed at decreased environmental nitrogen pollution from their manure such as nitrate leaching, nutrient-laden run-off and ammonia volatilization — their milk production can suffer. Supplementing the amino acid histidine may help in maintaining, and even increasing, milk and milk-protein yields. That’s the conclusion of a new study conducted by an international research team led by Alexander Hristov, Penn State distinguished ...

"Monstrous births” and the making of race in the nineteenth-century United States

2023-09-07

From the Middle Ages to the Enlightenment, “monstrous births”—malformed or anomalous fetuses—were, to Western medicine, an object of superstition. In 19th-century America, they became instead an object of the “modern scientific study of monstrosity,” a field formalized by French scientist Isidore Geoffroy Saint-Hilaire. This clinical turn was positioned against the backdrop of social, political, and economic activity that codified laws governing slavery, citizenship, immigration, family, ...

Moral reasoning displays characteristic patterns in the brain

2023-09-07

(Santa Barbara, Calif.) — Every day we encounter circumstances we consider wrong: a starving child, a corrupt politician, an unfaithful partner, a fraudulent scientist. These examples highlight several moral issues, including matters of care, fairness and betrayal. But does anything unite them all? Philosophers, psychologists and neuroscientists have passionately argued whether moral judgments share something distinctive that separates them from non-moral matters. Moral monists claim that morality is unified by a common characteristic and that all moral issues involve concerns about harm. Pluralists, in contrast, argue that moral ...

Echoes of extinctions: novel method unearths disruptions in mammal trait-environment relationships

2023-09-07

Large-bodied mammals play crucial roles in ecosystems. They create habitats, serve as prey, help plants thrive, and even influence how wildfires burn. But now, fewer than half of the large mammal species that were alive 50,000 years ago exist today, and those that remain are threatened with extinction from intensifying climate change and human activities. While mammal extinctions are well-documented, very little research has explored the impact those losses had on the nuanced ways in which mammal communities interact with their environments. Researchers at the Georgia Institute of Technology are using a novel methodology to investigate how mammals’ ability to function in their environments ...

Specialized T cells in the brain slow progression of Alzheimer’s disease

2023-09-07

(MEMPHIS, Tenn. – September 07, 2023) As many as 5.8 million Americans are currently living with Alzheimer’s disease, a neurodegenerative condition associated with progressive cognitive decline, including loss of memory capabilities . Protein aggregates, composed of beta-amyloid or other proteins, form in the brains of individuals with Alzheimer’s. These beta-amyloid plaques appear to be a significant contributor to the disease. St. Jude Children’s Research Hospital scientists uncovered a subset of immune cells that appears to slow this beta-amyloid plaque accumulation ...

KERI, transfer of ‘ion implantation evaluation technology for the SiC power semiconductor’ to Hungary

2023-09-07

KERI succeeded in transferring the ‘Ion Implantation and its Evaluation Technology for the SiC (silicon carbide) Power Semiconductor’ to a Hungarian company. Power semiconductors are key components in electricity and electronics, acting as the muscles of the human body by regulating the direction of current and controlling power conversion. There are many different materials for power semiconductors. Among them, SiC is receiving the most attention due to its excellent material properties, including high durability and excellent power efficiency. When SiC power ...

VCU liver institute director leads review of noninvasive tests that could be alternatives to painful biopsies

2023-09-07

By A.J. Hostetler Led by the director of Virginia Commonwealth University’s Stravitz-Sanyal Institute of Liver Disease and Metabolic Health, a consortium studying noninvasive tests for liver disease has demonstrated the effectiveness of five noninvasive tests, a significant milestone on the path to regulatory approval. In an article published today in the journal Nature Medicine, institute director Arun Sanyal, M.D., a professor at the VCU School of Medicine, and colleagues report on five biomarker tests that potentially could be given to patients who may have ...

Identification of chemical constituents and blood-absorbed components of Shenqi Fuzheng extract based on UPLC-triple-TOF/MS technology

Emergency department physicians vary widely in their likelihood of hospitalizing a patient, even within the same facility

Firearm and motor vehicle pediatric deaths— intersections of age, sex, race, and ethnicity

[Press-News.org] Psilocybin – a promising therapy for treatment-resistant depression?
Journal of Psychiatric Practice presents review and update on psychedelics for mental disorders

Psilocybin – a promising therapy for treatment-resistant depression?

ELSE PRESS RELEASES FROM THIS DATE:

LAST 30 PRESS RELEASES: